Cover Image
市場調查報告書

Hemagglutinin(血凝素)5 (H5):開發中產品分析

Hemagglutinin 5 (H5) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365800
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
Hemagglutinin(血凝素)5 (H5):開發中產品分析 Hemagglutinin 5 (H5) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 53 Pages
簡介

本報告提供以Hemagglutinin(血凝素)5 (H5)為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Hemagglutinin(血凝素)5 (H5) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Altravax, Inc.
  • Ilyang Pharmaceutical Co., Ltd
  • Inovio Pharmaceuticals, Inc.
  • NewLink Genetics Corporation
  • Vaxine Pty Ltd

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0318TDB

Summary

Global Markets Direct's, 'Hemagglutinin 5 (H5) - Pipeline Review, H1 2016', provides in depth analysis on Hemagglutinin 5 (H5) targeted pipeline therapeutics.

The report provides comprehensive information on the Hemagglutinin 5 (H5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hemagglutinin 5 (H5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Hemagglutinin 5 (H5)
  • The report reviews Hemagglutinin 5 (H5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hemagglutinin 5 (H5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hemagglutinin 5 (H5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hemagglutinin 5 (H5) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hemagglutinin 5 (H5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hemagglutinin 5 (H5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemagglutinin 5 (H5) Overview
  • Therapeutics Development
    • Hemagglutinin 5 (H5) - Products under Development by Stage of Development
    • Hemagglutinin 5 (H5) - Products under Development by Therapy Area
    • Hemagglutinin 5 (H5) - Products under Development by Indication
  • Hemagglutinin 5 (H5) - Pipeline Products Glance
    • Early Stage Products
  • Hemagglutinin 5 (H5) - Products under Development by Companies
  • Hemagglutinin 5 (H5) - Products under Development by Universities/Institutes
  • Hemagglutinin 5 (H5) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hemagglutinin 5 (H5) - Companies Involved in Therapeutics Development
    • Altravax, Inc.
    • Ilyang Pharmaceutical Co., Ltd
    • Inovio Pharmaceuticals, Inc.
    • NewLink Genetics Corporation
    • Vaxine Pty Ltd
  • Hemagglutinin 5 (H5) - Drug Profiles
    • DPC-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] (split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-3510 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IY-7640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit H5 HA and H7 HA for Avian Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VGX-3400X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hemagglutinin 5 (H5) - Dormant Projects
  • Hemagglutinin 5 (H5) - Featured News & Press Releases
    • Sep 06, 2012: Inovio Pharma Takes Major Stride Toward Universal Influenza Vaccine
    • Jul 10, 2012: Inovio Pharma Initiates Phase I H1N1 Universal Influenza Vaccine Clinical Trial
    • May 16, 2012: Inovio Pharma's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial
    • May 16, 2012: Inovio's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial
    • Mar 26, 2012: Inovio Receives US Patent For SynCon H1N1 Influenza Universal Vaccine
    • Jan 31, 2012: Inovio Pharmaceuticals Moves Closer To Universal Influenza Vaccine By Demonstrating Protective Immune Responses Against Multiple H3N2 And Type B Strains In Animal Studies
    • Nov 17, 2011: Inovio's Synthetic Avian Flu Vaccine Demonstrates Inhibition Of Multiple H5N1 Strains In Phase I Trial
    • Jul 14, 2011: Inovio Demonstrates Positive Immune Responses In Phase I Clinical Trial of SynCon H5N1 Influenza Vaccine
    • Jul 14, 2011: Inovio Launches Multi-Subtype Influenza Vaccine Phase I Trial
    • Sep 30, 2010: About Inovio's SynCon Universal Influenza Vaccines
    • Sep 30, 2010: Inovio's SynCon Universal Influenza DNA Vaccine Technology Recognized With NIH Director's Transformative Research Award
    • Jun 15, 2010: Inovio Immunizes First Subject In US Influenza DNA Vaccine Clinical Trial
    • Mar 02, 2010: Inovio Receives Korean Approval To Begin Clinical Trials Of H5N1 Avian Influenza DNA Vaccine
    • Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies
    • Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Altravax, Inc., H1 2016
  • Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2016
  • Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Pipeline by NewLink Genetics Corporation, H1 2016
  • Pipeline by Vaxine Pty Ltd, H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top